Investing
Divestiture and other proceeds
Bristol-Myers Squibb Divestiture and other proceeds increased by 28.4% to $312.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 28.4%, from $243.00M to $312.00M. Over 3 years (FY 2021 to FY 2024), Divestiture and other proceeds shows an upward trend with a 13.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementCash Flow Statement
SectionInvesting
CategoryCapital Allocation
SignalHigher is better
VolatilityVolatile
First reportedQ1 2020
Last reportedQ1 2026Apr 30, 2026
How to read this metric
Significant inflows indicate successful divestiture strategies or the shedding of non-core assets to focus on primary business lines.
Detailed definition
Captures cash inflows from the sale of business units, assets, or other non-core investments. This metric highlights the...
Peer comparison
Highly variable; depends on specific corporate restructuring events.
Metric ID:
investing_divestiture_and_other_proceedsHistorical Data
17 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $187.00M | $187.00M | $187.00M | $326.25M | $326.25M | $326.25M | $326.25M | $227.25M | $227.25M | $227.25M | $227.25M | $274.75M | $274.75M | $274.75M | $274.75M | $243.00M | $312.00M |
| QoQ Change | — | +0.0% | +0.0% | +74.5% | +0.0% | +0.0% | +0.0% | -30.3% | +0.0% | +0.0% | +0.0% | +20.9% | +0.0% | +0.0% | +0.0% | -11.6% | +28.4% |
| YoY Change | — | — | — | — | +74.5% | +74.5% | +74.5% | -30.3% | -30.3% | -30.3% | -30.3% | +20.9% | +20.9% | +20.9% | +20.9% | -11.6% | +28.4% |
Range$187.00M – $326.25M
CAGR+13.7%
Avg YoY Growth+15.6%
Median YoY Growth+20.9%
Divestiture and other proceeds at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's divestiture and other proceeds?
- Bristol-Myers Squibb (BMY) reported divestiture and other proceeds of $312.00M in Q1 2026.
- How has Bristol-Myers Squibb's divestiture and other proceeds changed year-over-year?
- Bristol-Myers Squibb's divestiture and other proceeds increased by 28.4% year-over-year, from $243.00M to $312.00M.
- What is the long-term trend for Bristol-Myers Squibb's divestiture and other proceeds?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's divestiture and other proceeds has grown at a 13.7% compound annual growth rate (CAGR), from $748.00M to $1.10B.
- What does divestiture and other proceeds mean?
- Cash received from selling business units or non-core assets.